title: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials.
abstract: OBJECTIVE
  To determine the ability of statins to prevent the development of new-onset type 2 diabetes mellitus through a meta-analysis of randomized, controlled trials.
  
  
  METHODS
  A systematic literature search through November 6, 2007 was conducted to identify randomized, placebo-controlled trials of statins that reported data on the incidence of new-onset diabetes mellitus. Incidence of new-onset type 2 diabetes mellitus was treated as a dichotomous variable. Weighted averages were reported as relative risk (RR) with associated 95% confidence intervals (CI). A random-effects model was used.
  
  
  RESULTS
  Five prospective, randomized controlled trials (n = 39,791) were identified. Upon meta-analysis, the use of a statin did not significantly alter a patient's risk of developing new-onset type 2 diabetes mellitus (relative risk, 1.03; 95% confidence interval 0.89-1.19). Subgroup and sensitivity analyses did not significantly change the results. There was statistical heterogeneity that stemmed from pravastatin's tendency towards a reduction in risk and the other statins showing an increase in risk. The funnel plot could not rule out publication bias.
  
  
  CONCLUSIONS
  Statins, as a class, do not demonstrate a statistically significant positive or negative impact on a patient's risk of developing new-onset type 2 diabetes mellitus.
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.forename: Kurt
authors.initials: K
authors.lastname: Reinhart
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Kluger
authors.forename: C Michael
authors.initials: CM
authors.lastname: White
mesh_terms: D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors